BayBio Notes
<< < 3 4 5 6 7 10 20 100 > >>
- Anacor Pharmaceuticals Announces First Quarter 2012 Financial Results Conference Call and Webcast - May 4, 2012
PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) will release its financial results for the quarter ended March 31, 2012, on Thursday, May 10, 2012 at approximately 4:00...
Read More... - FDA Official Says Drug Advances Could Get Boost from Academic Medical Centers - May 4, 2012
Academic medical centers can play a larger role in drug development and testing, according to an FDA official, who says there is a need for better strategies to identify winners, minimize costs and...
Read More... - Affymax Announces Upcoming Webcasts and Conference Participation - May 4, 2012
PALO ALTO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) today announced the company's participation in the following investor conferences during the month of May. Deutsche Bank 37th...
Read More... - UCSF Clinicians Get New Ammunition in Fight Against Childhood Cancers - May 4, 2012
Steven DuBois, a specialist in childhood cancers, and his colleagues at UCSF have access to a vastly expanded array of potential resources in their battle against childhood cancers now that they...
Read More... - Affymetrix and eBioscience Amend Definitive Merger Agreement - May 4, 2012
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc., (NASDAQ:AFFX) and eBioscience, Inc., a privately-held San Diego, CA-based company with an industry-leading position in flow cytometry and...
Read More... - Xoma zeroes in on diabetes — and a partnership? — again - May 4, 2012
<img src='http://assets.bizjournals.com/sanfrancisco/print-edition/JohnVarian*100.jpg?v=1'>Research was on the chopping block as Xoma Corp. looked to cut costs over the past year....
Read More... - Napo Comments on FDA Announcing Extension of Crofelemer NDA Priority Review - May 3, 2012
SAN FRANCISCO--(BUSINESS WIRE)--Napo Pharmaceuticals, Inc. (Napo) has been informed that the U.S. Food & Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date...
Read More... - Cardiovascular Safety Concerns Over Smoking-Cessation Drug Misleading - May 3, 2012
A popular smoking cessation medication has been under a cloud of suspicion ever since the Canadian Medical Association Journal published a study in July 2011 reporting “risk of serious adverse...
Read More... - Fluidigm Announces Timing for Release of First Quarter 2012 Financial Results - May 3, 2012
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Fluidigm Corporation (NASDAQ:FLDM) today announced that it will report its first quarter 2012 financial results on May 10, 2012, after close of market.
Read More... - Exelixis Announces First Quarter 2012 Financial Results - May 3, 2012
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the quarter ended March 31, 2012. The financial results for the quarter reflect...
Read More... - Affymetrix Reports First Quarter 2012 Results - May 3, 2012
SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc., (NASDAQ:AFFX) today reported its operating results for the first quarter of 2012. Total revenue for the quarter was $65.2 million, as...
Read More... - Safety Concerns Over Smoking-Cessation Drug Misleading - May 3, 2012
A popular smoking cessation medication has been under a cloud of suspicion ever since the Canadian Medical Association Journal published a study in July 2011 reporting “risk of serious adverse...
Read More... - FibroGen Announces Promising Preliminary Data from an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals with Idiopathic Pulmonary Fibrosis (IPF) and Provides Program Update - May 3, 2012
SAN FRANCISCO--(BUSINESS WIRE)--Biotechnology company FibroGen decides to expand ongoing Phase 2 study of investigational antifibrotic therapy, FG-3019, in patients with idiopathic pulmonary...
Read More... - Rats Recall Past to Make Daily Decisions - May 3, 2012
UCSF scientists have identified patterns of brain activity in the rat brain that play a role in the formation and recall of memories and decision-making. The discovery, which builds on the team’s...
Read More... - Oraya Therapeutics Achieves Successful INTREPID Study Outcomes with a Non-Invasive Radiation Therapy for Wet AMD - May 3, 2012
NEWARK, Calif.--(BUSINESS WIRE)--Oraya Therapeutics, Inc.'s INTREPID clinical trial of radiation therapy has met its primary endpoint of reduction in anti-VEGF injections for patients with wet...
Read More... - Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration - May 3, 2012
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ:EXEL) today announced a broad expansion of the cabozantinib development program under a Cooperative Research and Development...
Read More... - Virtual Biotech Companies: Built on Solid Bedrock or Unstable Landfill? - May 3, 2012
Read More... - Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous Injection - May 3, 2012
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the SUMMACTA study met its primary endpoint, showing...
Read More... - Genomic Health, OncoMed Team Up on Personalized Cancer Drug Work - May 2, 2012
Read More... - Exelixis Announces May 8th Webcast of Presentation at the Deutsche Bank Securities 37th Annual Health Care Conference - May 2, 2012
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) announced today that Frank Karbe, the company’s executive vice president and chief financial officer, will present at...
Read More...
